Literature DB >> 8867106

ML-7 and W-7 facilitate thromboxane A2-mediated Ca2+ mobilization in rabbit platelets.

S Ohkubo1, N Nakahata, Y Ohizumi.   

Abstract

The effects of 1-(5-iodonaphthalene-1-sulfonyl)-1H-hexahydro-1,4-diazepine (ML-7), a myosin light chain kinase inhibitor, and (N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide (W-7), a calmodulin antagonist, on thromboxane A2 receptor-mediated signal transduction were examined in rabbit washed platelets. ML-7 and W-7 at 10-30 microM slightly potentiated the aggregation induced by a thromboxane A2 receptor agonist, 9,11-dideoxy-9 alpha,11 alpha- epoxymethanoprostaglandin F2 alpha (U46619), in spite of their known inhibitory actions. ML-7 and W-7 concentration-dependently enhanced U46619-induced phosphoinositide hydrolysis and the increase in internal free Ca2+ concentration in the presence or absence of external Ca2+. While ML-7 and W-7 inhibited basal GTPase activity, they augmented U46619-induced activation of GTPase in a concentration-dependent manner. The present results suggest that ML-7 and W-7 enhance thromboxane A2 receptor-mediated signal transduction at the receptor/G protein coupling, leading to the enhancement of phosphoinositide hydrolysis and Ca2+ mobilization, independently of the inhibition of myosin light chain kinase or calmodulin.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8867106     DOI: 10.1016/0014-2999(95)00788-1

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  2 in total

1.  Effects of valproate on serotonin-induced intracellular calcium mobilization in human platelets.

Authors:  Tatsuyuki Akimoto; Ichiro Kusumi; Katsuji Suzuki; Takuya Masui; Tsukasa Koyama
Journal:  J Psychiatry Neurosci       Date:  2007-01       Impact factor: 6.186

2.  Calmodulin antagonists induce cell cycle arrest and apoptosis in vitro and inhibit tumor growth in vivo in human multiple myeloma.

Authors:  Shigeyuki Yokokura; Saki Yurimoto; Akihito Matsuoka; Osamu Imataki; Hiroaki Dobashi; Shuji Bandoh; Takuya Matsunaga
Journal:  BMC Cancer       Date:  2014-11-26       Impact factor: 4.430

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.